Last updated: 2026-09-06 21:42:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Pluri Inc. (PLUR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1,37, with a market capitalization of $17,03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,25 to $5,29. This page covers its latest market performance, valuation, price trends and company information.
$17,03M | |
$1,44 | |
$11,58 | |
$1,25 | |
$1,37 | |
15,44K | |
-- | |
-- | |
$5,29 | |
$1,25 | |
-- | |
-- |
Pluri Inc. (PLUR) last closed at $1,37 as of 2026-09-04 20:11:00, unchanged from the previous close of $1,37.
During the latest regular trading session, PLUR traded between $1,25 and $11,58, with a volume of 15,44K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Pluri Inc. (PLUR) moved from $1,53 to $1,37, representing a decline of 10,72% ($0,16).
The stock traded between $1,34 and $1,45 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 35,18 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2,9%
PLUR is currently trading at $1,37, placing it 2,9% of the way from its 52-week low of $1,25 to its 52-week high of $5,29. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 142 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pluri Inc. (PLUR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.